Apogee Therapeutics (NASDAQ:APGE) vs. Tyra Biosciences (NASDAQ:TYRA) Financial Comparison

Tyra Biosciences (NASDAQ:TYRA) and Apogee Therapeutics (NASDAQ:APGE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.

Volatility and Risk

Tyra Biosciences has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.

Profitability

This table compares Tyra Biosciences and Apogee Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Insider & Institutional Ownership

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Tyra Biosciences and Apogee Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1	1	12	1	2.87
Apogee Therapeutics	1	15	4	1	2.24

Tyra Biosciences presently has a consensus price target of $46.90, indicating a potential upside of 76.91%. Apogee Therapeutics has a consensus price target of $121.25, indicating a potential downside of 10.08%. Given Tyra Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Apogee Therapeutics.

Valuation and Earnings

This table compares Tyra Biosciences and Apogee Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95 million	($2.40)	-11.05
Apogee Therapeutics	N/A	N/A	-$255.84 million	($4.33)	-31.14

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Tyra Biosciences beats Apogee Therapeutics on 8 of the 11 factors compared between the two stocks.

About Tyra Biosciences

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

About Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.